Want to see CBLL full AI Analyst Report?
Revenue by Type
Breaks down sales into hardware, consumables (disposables), service contracts and any recurring software/subscription revenue. For Ceribell, distinguishing one‑time device sales from repeat purchases or subscription fees shows how predictable future cash flow is, where margins tend to be higher, and which parts of the business drive growth. Heavy reliance on one‑time device sales can make results lumpy, while growth in consumables and subscriptions signals stickier customers and better long‑term revenue visibility; reimbursement changes, hospital adoption rates, and supply‑chain constraints are key risks to monitor.Recorders/wearables are driving the bulk of Ceribell’s revenue acceleration while subscriptions are growing faster percentage‑wise but remain a smaller, improving recurring slice—so top‑line momentum is real but not yet predominantly recurring. Management’s Q1 commentary (strong account adds, high gross margins, raised guidance) confirms commercial traction; however, elevated operating expenses, litigation and seasonality in ICU volumes keep profitability pressured near term. Reimbursement wins (NTAP) and delirium/pediatric rollouts are meaningful upside that could materially improve revenue quality in 2027+.
Date | EEG Recorders & Wearables Sales | EEG Portal & Clarity Subscriptions & Recorder Loans |
|---|---|---|
Jun 30, 2026 | $21.24M | $6.86M |
Mar 31, 2026 | $20.19M | $6.30M |
Dec 31, 2025 | $18.78M | $6.00M |
Sep 30, 2025 | $17.02M | $5.57M |
Jun 30, 2025 | $15.92M | $5.28M |
Mar 31, 2025 | $15.61M | $4.88M |
Dec 31, 2024 | $14.15M | $4.39M |
Sep 30, 2024 | $13.32M | $3.87M |
Jun 30, 2024 | $11.58M | $3.74M |
Mar 31, 2024 | $11.04M | $3.37M |